YIFAN PHARMACEUTICAL CO's Total Assets for the quarter that ended in Mar. 2024 was ¥11,781 Mil.
During the past 12 months, YIFAN PHARMACEUTICAL CO's average Total Assets Growth Rate was -3.60% per year.
During the past 3 years, the average Total Assets Growth Rate was 1.20% per year.
During the past 5 years, the average Total Assets Growth Rate was 6.00% per year.
During the past 10 years, the average Total Assets Growth Rate was 24.90% per year.
During the past 13 years, YIFAN PHARMACEUTICAL CO's highest 3-Year average Total Assets Growth Rate was 129.80%. The lowest was -21.00%. And the median was 20.00%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
YIFAN PHARMACEUTICAL CO's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
YIFAN PHARMACEUTICAL CO (SZSE:002019) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Mar. 2024) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
YIFAN PHARMACEUTICAL CO's Asset Turnover for the quarter that ended in Mar. 2024 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
YIFAN PHARMACEUTICAL CO Total Assets Related Terms
Thank you for viewing the detailed overview of YIFAN PHARMACEUTICAL CO's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
YIFAN PHARMACEUTICAL CO (SZSE:002019) Business Description
YIFAN PHARMACEUTICAL CO LTD is a China-based company engaged in pharmaceutical innovation and manufacturing. The company focuses its activities on key areas like macromolecular biologics, high-value pharmaceuticals, and differentiated traditional Chinese medicines. The products of the company are F-627 for Neutropenia and Parkinson's disease, F-652 for acute alcoholic hepatitis, GvHD and acute pancreatitis and F-899 for growth deficiency. The company's products are sold in China and internationally.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SZSE:002019 has been successfully added to your 